BMS entered the radiopharma space via its $4.1 billion buyout of RayzeBio at the end of 2023. Unlike Novartis’ approved ...

Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead ...

Fabricated via thermal evaporation, the champion perovskite-perovskite-silicon triple-junction solar cell reached an ...

The phase 3 VALOR-HCM trial in adults with obstructive HCM eligible for a procedure called septal reduction therapy (SRT) met its primary endpoint, according to BMS. The aim of the study is to ...

Grid-scale battery energy storage system (BESS) installations have advanced significantly, incorporating technological ...

Philochem AG’s ligand-targeting approach drew to the table Bristol Myers Squibb Co. in a potential $1.35 billion agreement granting BMS subsidiary Rayzebio Inc. exclusive worldwide rights to OncoACP3, ...

The $1.35 billion deal is expected to close in Q3 2025, giving RayzeBio rights to the radioligand, which is already undergoing Phase I testing as a diagnostic.

This project demonstrates the **design of a 6-Transistor (6T) SRAM memory cell** using the **Electric VLSI Design System**. It includes only the **schematic and layout**—simulation and waveform ...